The Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive (TSO) at $2,989.55 per test under PLA code 0543U, effective Jan. 1, 2026. The decision removes a major reimbursement barrier for comprehensive genomic profiling (CGP) in solid tumors and could accelerate clinical adoption in community and academic oncology settings. Illumina said the FDA‑cleared assay interrogates more than 500 genes and is approved as a companion diagnostic for select NTRK and RET fusion‑positive indications. Market‑access teams expect the payment decision to expand use of CGP for therapy selection and enrollment in targeted‑therapy trials. Payers, providers and diagnostic labs will evaluate how the CMS rate aligns with private‑payer coverage; developers of competing CGP assays may also adjust commercialization plans in response to the new Medicare signal.